Anzeige
Mehr »
Login
Sonntag, 23.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
851 % Rendite in 30 Tagen: Die KI-Aktie, die seit der Integration von Deepseek R1 Wellen schlägt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EURE | ISIN: CA71716W2040 | Ticker-Symbol: G11
München
21.02.25
08:15 Uhr
0,001 Euro
-0,002
-75,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMADRUG INC Chart 1 Jahr
5-Tage-Chart
PHARMADRUG INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0050,01919:04

Aktuelle News zur PHARMADRUG Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.11.24Pharmadrug Inc (2): Pharmadrug issues debenture units to replace debentures11
15.11.24PharmaDrug Inc.: PharmaDrug Announces Issuance of Debenture Units741Toronto, Ontario--(Newsfile Corp. - November 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
PHARMADRUG Aktie jetzt für 0€ handeln
31.10.24Pharmadrug Inc (2): Pharmadrug to issue $414,523 in debenture units1
31.10.24PharmaDrug Inc.: PharmaDrug Announces Proposed Issuance of Debenture Units409Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
31.10.24Pharmadrug Inc (2): Pharmadrug completes PD-001 stability study2
31.10.24PharmaDrug Inc.: PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases261Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
20.09.24PharmaDrug Subsidiary Begins Prep Work For Clinical Trial Of PD-001 For Viral Infectious Diseases4
19.09.24Pharmather Holdings Ltd: Pharmadrug begins start-up work for PD-001 study2
19.09.24Pharmadrug Inc (2): Pharmadrug begins start-up work for PD-001 study2
19.09.24PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases275Toronto, Ontario--(Newsfile Corp. - September 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research,...
► Artikel lesen
28.08.24Pharmadrug Inc (2): Pharmadrug details plans for cepharanthine development2
28.08.24Pharmather Holdings Ltd: Pharmadrug details plans for cepharanthine development3
28.08.24PharmaDrug Subsidiary To Focus Development Of PD-001 On Viral Infectious Diseases1
28.08.24PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases434Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
21.08.24PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins483Toronto, Ontario--(Newsfile Corp. - August 21, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
19.08.24PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine452Toronto, Ontario--(Newsfile Corp. - August 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
23.05.24PharmaDrug Inc.: Pharmadrug's Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine322Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
15.05.24PharmaDrug Inc.: PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine264Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
13.05.24PharmaDrug Inc.: PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization326Toronto, Ontario--(Newsfile Corp. - May 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
02.05.24PharmaDrug Inc.: PharmaDrug Announces Director Appointment and Resignation752Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3